Supplement analysis backed by scientific evidence · PT

← All supplements
Moderate evidenceHeart & metabolic

Berberine

Berberine genuinely lowers blood glucose and LDL cholesterol, with effect sizes in the same range as low-dose metformin — but almost all trials are small, short and from a single region, and the methodological quality is poor. It is a pharmacologically active compound with real drug interactions, not a gentle herbal.

What the science says

  • Lowers blood glucose in type 2 diabetes Moderate evidence

    A meta-analysis of 27 RCTs (2,569 patients) found berberine added to lifestyle intervention reduced fasting glucose, postprandial glucose and HbA1c more than lifestyle alone, and berberine plus oral hypoglycaemics beat those drugs alone. Head-to-head against metformin or other oral hypoglycaemics there was no statistically significant difference. The caveat is large: nearly all included trials were small, conducted in China, and at high risk of bias.

  • Improves the lipid profile Moderate evidence

    Pooling 16 RCTs in 2,147 people with dyslipidaemia, berberine lowered total cholesterol by 0.47 mmol/L (95% CI -0.64 to -0.31), LDL-C by 0.38 mmol/L (95% CI -0.53 to -0.22) and triglycerides by 0.28 mmol/L, and raised HDL-C by 0.08 mmol/L when used alone. Adverse event rates did not differ from control (RR 0.64). Clinical heterogeneity was high and most trials had weak randomisation, allocation concealment and blinding.

  • Body weight and metabolic syndrome markers Limited evidence

    Weight changes reported alongside glycaemic trials are typically under 2 kg over 8-12 weeks and are secondary outcomes in studies not designed to measure them. There is no adequately powered, long-term trial of berberine for weight loss.

  • Bioavailability is the core problem Moderate evidence

    Oral berberine has absolute bioavailability under 1%, so systemic drug levels are far below what its in vitro potency would suggest, and much of the effect may be mediated in the gut and by gut microbiota. This makes results highly dependent on formulation and dose timing, and partly explains the heterogeneity between trials.

Dosage & safety

Studied doseTrials typically used 0.9-1.5 g/day of berberine hydrochloride, split into 2-3 doses of 500 mg taken with or just after meals, for 8-12 weeks. Doses above 1.5 g/day mainly increase gastrointestinal side effects. Dosing beyond 6 months has not been well studied.
SafetyGastrointestinal effects are common and dose-related: constipation, diarrhoea, cramping, flatulence and nausea, affecting up to a third of users at higher doses. Berberine inhibits CYP3A4, CYP2D6 and P-glycoprotein, so it can substantially raise blood levels of statins, cyclosporine, midazolam, dextromethorphan and many other drugs — a real interaction risk, not a theoretical one. Combined with insulin, metformin or sulfonylureas it can cause additive hypoglycaemia. Contraindicated in pregnancy and breastfeeding, and must not be given to neonates or infants: berberine displaces bilirubin from albumin and has been linked to kernicterus risk. Not a substitute for prescribed glucose- or lipid-lowering therapy.

Scientific references

Where to buy

Nutricost, Berberine HCl With Ceylon Cinnamon, 120 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Heart & metabolic